je.st
news
Regeneron Pharmaceuticals Given "Outperform" Rating at RBC Capital
2015-06-06 21:12:59| Biotech - Topix.net
REGN has been the subject of a number of other recent research reports. Analysts at Piper Jaffray reiterated a "neutral" rating and set a $484.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, May 21st.
Tags: rating
capital
pharmaceuticals
rbc
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||